Maintenance of remission with infliximab in inflammatory bowel disease: Efficacy and safety long-term follow-up

Table 2 Efficacy profile of maintenance protocol

	IBD (CD + UC)		Crohn's disease		Ulcerative colitis
IFX infusions total number	637		493		144
Median number (range)	15 (4-25)		15 (4-25)		14.5 (6-22)
Median duration (mo) of IFX therapy (range)	27 (4-64)		27 (4-64)		24.5 (6-46)
No. patients maintaining remission with IFX (%)	41/50	82	32/40	80	9/10	90
Median duration (mo) of remission during IFX treatment (range)	25 (4-59)		25.5 (4-59)		25 (6-46)
No. patients discontinuing therapy during clinical remission (%)	13/38	34	9/29	31	4/9	44
Median duration (mo) of remission after treatment discontinuation (range)	15.5 (4-30)		16 (5-30)		6.5 (4-16)
No. patients on corticosteroids1 during maintenance with IFX (%)	1/50	2	10/40	25	1/10	10

¹Median corticosteroid dose ≤ 0.25 mg/kg per day.